SSG
XERS icon

Summit Securities Group’s Xeris Biopharma Holdings XERS Stock Holding History

Summit Securities Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,497
Closed -$67.7K – 1401
2025
Q2 		$67.7K Buy
+14,497
New +$66.4K 0.01% 438

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Summit Securities Group's XERS Position: Q3 2025 in Review

Summit Securities Group sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 14,497 shares — an estimated $67.7K sold.

Summit Securities Group first reported a position in XERS in Q2 2025 and held it in 1 quarter. The position peaked at $67.7K in Q2 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

  • Summit Securities Group reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 14,497 Xeris Biopharma Holdings shares in Q3 2025, an estimated $67.7K.
  • Summit Securities Group first reported a position in Xeris Biopharma Holdings in Q2 2025 and held it in 1 quarter.
  • Summit Securities Group's Xeris Biopharma Holdings position peaked at $67.7K in Q2 2025.
  • 230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.